Merck & Co., Inc. (MRK) Release: FDA Approves PROQUAD(R), The First And Only Vaccine In The U.S. To Help Protect Children Against Measles, Mumps, Rubella And Chickenpox In One Shot 
10/19/2005 5:09:14 PM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Sept. 6, 2005--Merck & Co., Inc. today announced that the U.S. Food and Drug Administration has approved the Company's combination vaccine PROQUAD(R) (Measles, Mumps, Rubella and Varicella (Oka/Merck) Virus Vaccine Live) for simultaneous vaccination against measles, mumps, rubella (German measles) and varicella (chickenpox) in children 12 months to 12 years of age. PROQUAD is the first and only vaccine approved in the United States to help protect against these four diseases in a single shot. PROQUAD is also approved for use in children 12 months to 12 years of age if a second dose of measles, mumps, and rubella vaccine is to be administered.